
GSK, formerly Glaxosmithkline, has reported positive data from its RSV vaccine trial, Bloomberg News reports.
The media says that this is a boost for the firm, as it is preparing to split its Haleon user healthcare division into a separate unit.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app